Parallel Evolution of Host-Attachment Proteins in Phage PP01 Populations Adapting to Escherichia coli O157:H7
暂无分享,去创建一个
Paul E. Turner | P. Turner | E. S. Williams | J. Wertz | John E. Wertz | B. Chan | Benjamin K. Chan | Chidiebere Akusobi | Elizabeth S.C.P. Williams | Chidiebere Akusobi
[1] M. Hochberg,et al. Contrasted coevolutionary dynamics between a bacterial pathogen and its bacteriophages , 2014, Proceedings of the National Academy of Sciences.
[2] B. Hargis,et al. Ability of bacteriophages isolated from different sources to reduce Salmonella enterica serovar enteritidis in vitro and in vivo. , 2007, Poultry science.
[3] M. Rossmann,et al. Morphogenesis of the T4 tail and tail fibers , 2010, Virology Journal.
[4] H. Krisch,et al. Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesin specificity. , 1998, Journal of molecular biology.
[5] J. Pirnay,et al. Guidelines to Compose an Ideal Bacteriophage Cocktail. , 2018, Methods in molecular biology.
[6] P. Turner,et al. Laboratory-Dependent Bacterial Ecology: a Cautionary Tale , 2006, Applied and Environmental Microbiology.
[7] K. Heller. Molecular interaction between bacteriophage and the gram-negative cell envelope , 2004, Archives of Microbiology.
[8] I. Wang,et al. Bacteriophage Adsorption Rate and Optimal Lysis Time , 2008, Genetics.
[9] R. Lenski,et al. The fate of competing beneficial mutations in an asexual population , 2004, Genetica.
[10] K. Miyanaga,et al. Toward rational control of Escherichia coli O157:H7 by a phage cocktail , 2004, Applied Microbiology and Biotechnology.
[11] Curt R. Fischer,et al. Amino acid alterations in Gp38 of host range mutants of PP01 and evidence for their infection of an ompC null mutant of Escherichia coli O157:H7. , 2002, FEMS microbiology letters.
[12] M. Hochberg,et al. Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1 , 2013, Evolutionary applications.
[13] J. Draghi,et al. High-throughput analysis of growth differences among phage strains. , 2012, Journal of microbiological methods.
[14] J. Gill,et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. , 2010, The Journal of infectious diseases.
[15] Lindsey W. McGee,et al. Mutation-Driven Parallel Evolution during Viral Adaptation , 2017, Molecular biology and evolution.
[16] Jeffrey E. Barrick,et al. Repeatability and Contingency in the Evolution of a Key Innovation in Phage Lambda , 2012, Science.
[17] Forest Rohwer,et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection , 2017, Antimicrobial Agents and Chemotherapy.
[18] A. Buckling,et al. Experimental evolution and bacterial resistance: (co)evolutionary costs and trade-offs as opportunities in phage therapy research , 2015, Bacteriophage.
[19] John A Elefteriades,et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa , 2018, Evolution, medicine, and public health.
[20] S. Sillankorva,et al. Bacteriophage Therapy , 2018, Methods in Molecular Biology.
[21] J. Bull,et al. Different trajectories of parallel evolution during viral adaptation. , 1999, Science.
[22] Curt R. Fischer,et al. Coevolution of Bacteriophage PP01 and Escherichia coli O157:H7 in Continuous Culture , 2003, Applied and Environmental Microbiology.
[23] R. Morona,et al. Host range mutants of bacteriophage Ox2 can use two different outer membrane proteins of Escherichia coli K-12 as receptors , 1984, Journal of bacteriology.
[24] I. Riede. Receptor specificity of the short tail fibres (gp12) of T-even type Escherichia coli phages , 2004, Molecular and General Genetics MGG.
[25] A. Abdulamir. Novel methods to design wild bacteriophages into highly lytic and therapeutic bacteriophages to extensively drug-resistant Mycobacterium tuberculosis , 2016, Journal of the Faculty of Medicine Baghdad.
[26] R. P. Ross,et al. Evaluation of a Cocktail of Three Bacteriophages for Biocontrol of Escherichia coli O157:H7 , 2004, Applied and Environmental Microbiology.
[27] E. Bingen,et al. Efficacy of Bacteriophage Therapy in Experimental Sepsis and Meningitis Caused by a Clone O25b:H4-ST131 Escherichia coli Strain Producing CTX-M-15 , 2012, Antimicrobial Agents and Chemotherapy.
[28] A. Buckling,et al. Pre‐adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates , 2016, Journal of evolutionary biology.
[29] M. Eschbach,et al. DNA sequence of the tail fiber genes 37, encoding the receptor recognizing part of the fiber, of bacteriophages T2 and K3. , 1986, Journal of molecular biology.
[30] S. Remold,et al. Generalized Growth of Estuarine, Household and Clinical Isolates of Pseudomonas aeruginosa , 2018, Front. Microbiol..
[31] Kunli Qu,et al. Use of Bacteriophages to Control Escherichia coli O157:H7 in Domestic Ruminants, Meat Products, and Fruits and Vegetables. , 2017, Foodborne pathogens and disease.
[32] M. Eschbach,et al. Receptor specificity of the Escherichia coli T-even type phage Ox2. Mutational alterations in host range mutants. , 1989, Journal of molecular biology.
[33] H. Unno,et al. Rapid Detection of Escherichia coli O157:H7 by Using Green Fluorescent Protein-Labeled PP01 Bacteriophage , 2004, Applied and Environmental Microbiology.
[34] H. Unno,et al. Characterization of a virulent bacteriophage specific for Escherichia coli O157:H7 and analysis of its cellular receptor and two tail fiber genes. , 2002, FEMS microbiology letters.
[35] J. Powers,et al. Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Y. Tseng,et al. Wide Host Range and Strong Lytic Activity of Staphylococcus aureus Lytic Phage Stau2 , 2010, Applied and Environmental Microbiology.
[37] K. Miyanaga,et al. Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. , 2005, Journal of biotechnology.
[38] H. Krisch,et al. The gp38 Adhesins of the T4 Superfamily: A Complex Modular Determinant of the Phage’s Host Specificity , 2011, Genome biology and evolution.
[39] O. Cars,et al. The global need for effective antibiotics: challenges and recent advances. , 2010, Trends in pharmacological sciences.
[40] C. Hill,et al. Bacteriophages ϕMR299-2 and ϕNH-4 Can Eliminate Pseudomonas aeruginosa in the Murine Lung and on Cystic Fibrosis Lung Airway Cells , 2012, mBio.
[41] E. Goldberg,et al. Cooperative action of the T4 tail fibers and baseplate in triggering conformational change and in determining host range. , 1976, Virology.
[42] Mark J. Sistrom,et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa , 2016, Scientific Reports.
[43] M. Eschbach,et al. DNA sequence of genes 38 encoding a receptor-recognizing protein of bacteriophages T2, K3 and of K3 host range mutants. , 1987, Journal of molecular biology.